A naturally occurring byproduct of liver metabolism—the ketone body, β-hydroxybutyrate (BHB)—can strengthen the fitness and antitumor activity of CAR T cells. The findings, reported on March 6, 2026 ...

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite prostaglandin E2 can block T cells—the killer cells of the immune system—in the ...

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

Kathmandu, March 7 -- Nepal has approved its first domestically manufactured CAR T-cell therapy for clinical use, marking a milestone in the country's cancer treatment capabilities. The Department of ...

Chimeric antigen receptor (CAR) T cell therapy improves the detection and elimination of cancerous cells by genetically editing a patient’s immune cells to target tumor-associated antigens. This type ...